Ann Martin, MD
Dermatology · Saint Louis, MONPI 1225056732
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,400 of the $1,631 with a category attached, or 85.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $699 and has fallen 87.9% since, to $84 in 2025. That places this record below the midpoint for dermatology clinicians in MO, where the typical reported total is $3,173.
Across 65 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$328
- Galderma Laboratories, L.p.$196
- Sun Pharmaceutical Industries Inc.$149
- Incyte Corporation$128
- Pfizer$119
- Regeneron Healthcare Solutions, Inc.$110
- plus $602 from 14 others
Across 78 payments — averaging $6555.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$301K
- E.r. Squibb & Sons, L.L.C.$124K
- Incyte Corporation$86K
- Glenmark Pharmaceuticals Inc., USA$553
What the payments were for
- Food & beverage$1,40086%
- Education$23114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $328 |
| Galderma Laboratories, L.p. | 8 | $196 |
| Sun Pharmaceutical Industries Inc. | 5 | $149 |
| Incyte Corporation | 1 | $128 |
| Pfizer | 6 | $119 |
| Regeneron Healthcare Solutions, Inc. | 2 | $110 |
| UCB, Inc. | 1 | $102 |
| Gilead | 1 | $86 |
| Lilly USA, LLC | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Boehringer Ingelheim | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Arcutis Biotherapeutics, Inc. | 1 | $38 |
| Biofrontera Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,631 in reported general payments places this provider in the 30th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 23 | $203,677 |
| Humira(Cf) PenAdalimumab | 12 | $96,695 |
| OtezlaApremilast | 13 | $69,624 |
| Dupixent PenDupilumab | 13 | $46,214 |
| Dupixent SyringeDupilumab | 12 | $43,706 |
| Clobetasol Propionate | 165 | $10,353 |
| Triamcinolone Acetonide | 263 | $3,853 |
| Econazole Nitrate | 119 | $3,019 |
| Tacrolimus | 11 | $2,871 |
| Ketoconazole | 155 | $2,832 |
| Doxycycline Hyclate | 102 | $2,682 |
| Fluocinonide | 63 | $2,502 |
| Clindamycin Phosphate | 58 | $2,443 |
| Tretinoin | 30 | $2,173 |
| ErythromycinErythromycin Base | 11 | $1,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $16 | $69,62413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 263 dermatology providers in Missouri.
Other dermatology in Saint Louis
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Mary GeorgeSaint Louis$400K
- Duane DilworthSaint Louis$288K
- Jeffrey ReedSaint Louis$170K
- Emily ColeSaint Louis$163K
- Dee GlaserSaint Louis$131K
- Milan AnadkatSaint Louis$129K
- Jason AmatoSaint Louis$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.